Aggressive forms of cancer can be devastating to patients and their families. This kind of diagnosis brings uncertainties about the quality of life and the length of time a patient has left. Healthcare company Novocure (NASDAQ: NVCR) aims to improve both these aspects for patients.
Novocure approaches cancer treatments differently than most of its peers; it uses electric fields to disrupt cancer cell division, and the frequency it uses does not affect healthy cells. In its investor presentation, Novocure noted a normal intestine cell has a natural frequency of 50 kHz. However, several cancer cells types have a natural frequency in the 150 kHz to 200 kHz range. With a wide effective treatment zone gap, Novocure's products disrupt the harmful cells while ignoring the healthy ones.
For further details see:
This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping?